Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. Its portfolio includes Core Lab and artificial intelligence (AI)-powered products to partner with clinicians and radiologists for diagnosis, and management of patients. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. Its other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart. The company operates as the Clinical Trial Research Organisation (CRO) and local sponsor for a major global pharma company's clinical trial in Australia of a new drug compound.